By clicking “Accept”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.

Regenerative Precision Medicine for Chronic Inflammation

Transgenion’s development grants a groundbreaking new pharmaceutical development for age-related chronic inflammation and a blessing for hundreds of millions of patients in the aging societies of the world. We invite you to join our exceptional team.

Research Areas

Status Quo: Decades of incomplete medical and biomolecular targeting

Transgenion’s strategy has overcome this dilemma by a successful combination of medical and biomolecular research (twenty years, twenty million Euros in public, not refundable funds) creating a groundbreaking set of clinically validated biomarkers ready to serve as targets for precision medicine in Chronic Inflammatory Diseases and Progressive Fibrosis.

In particular, this concerns two major diseases specific for advanced age:

Chronic Obstructive Pulmonary Disease
Idiopathic Pulmonary Fibrosis
Research Areas

Opportunity for the advancement of all CID treatments

Starting with the CORE Programs, Transgenion is realizing the first useful diagnosis and causal treatment for all CIDs. Initial successes have been observed in research for tumor diseases, which make up to 30% of all diseases onwards the age of 50. The group of CIDs is still urgently awaiting a successful combination of personalized diagnosis and therapy, and that's exactly where Transgenion comes into play!

The completion of CORE-1 marks the equivalent pharmaceutical development value at € 450 Mio.

The Transgenion Advantage

Currently at Technical Readiness Level 6

Technology demonstrated in relevant environment
Successful Clinical Pilot Study

Complete analysis for all clinically relevant markers in lung tissue based on 3-year observation per subject, representing COPD progression over more than 30 years.

Sequential Recording

First-time sequential recording of all relevant markers throughout the entire COPD course (from the risk stage to end-stage).

Unique Dataset

Unique dataset fully patented (25 patents across US, Europe and Japan).

>10 Years Market Lead

In summary, this results in a market lead of at least 10 years.

Frequently Asked Questions

What is COPD?

Chronic Obstructive Pulmonary Diesase (COPD) is a common lung disease causing obstructed airflow, breathing problems and exhaustion due to chronic bronchitis and emphysema.

What are the symptoms of COPD?

The most common symptoms of COPD are difficulty of breathing, chronic cough and feeling tired. COPD symptoms can get worse quickly. These are called flare-ups or exacerbations and last usually for a few days requiring additional medicine.

Consequences of COPD?

People with COPD have a higher risk for other health problems, such as lung infections, lung cancer, heart problems, depression etc.

Is COPD curable?

Unfortunately not! It can be treated with medicines, oxygen and pulmonary rehabilitation.

What is a biomarker?

A biomarker is a measurable substance or characteristic in the body that can indicate the presence or progression of a disease or condition. It can be a molecule, gene, protein, or another measurable feature that can be detected in blood, urine, tissue, or other bodily fluids.

In which field biomarkers are used?

Biomarkers are used in medical research and clinical practice to diagnose diseases, monitor treatment effectiveness, and predict patient outcomes.

What does predictive diagnosis in COPD mean?

A predictive diagnosis refers to the use of biomarkers or other indications to predict the development or progression of the disease. This can help identify individuals who are at a higher risk of developing COPD or those who may experience a more severe form of the disease.

What is the influence of Artificial intelligence in clinical studies?

AI will revolutionize clinical studies by enhancing data analysis, improving patient recruitment and selection, enabling predictive modeling, facilitating image analysis, accelerating drug discovery, enabling remote monitoring and enhancing literature review processes.

Still have questions?

Feel free to send us a message, and we'll get in touch promptly.

Unique Investment Opportunity

The future of Personalized Medicine for healthy aging has started. Seize this unprecedented opportunity to be a pioneer in the Personalized Medicine movement!

Explore how Transgenion is leading a groundbreaking transformation in the battle against COPD and various respiratory conditions.

Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease (COPD) is a progressive and debilitating respiratory condition characterized by persistent airflow limitation. This article provides a comprehensive review of COPD, including its description, pathology, epidemiology, and treatment strategies.

Overview of the socioeconomic burden imposed by COPD

The socioeconomic impact of Chronic Obstructive Pulmonary Disease (COPD) is substantial, affecting individuals, families, and healthcare systems worldwide. COPD imposes both direct and indirect costs, encompassing medical expenses, lost productivity, and diminished quality of life.

Inventor of the Year 2016 by Medical University of Vienna

Rolf Ziesche from the Clinical Department of Pulmonology at the University Clinic for Internal Medicine II of the Medical University of Vienna was elected 'Inventor of the Year 2016' by the Medical University of Vienna.

Get in Touch!

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.